Dr. Yu Compares Treatment Options for Prostate Cancer

James B. Yu, MD
Published: Friday, Aug 04, 2017



James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses radiotherapy versus surgery for patients with prostate cancer.

There is no survival difference between active surveillance and local therapy such as surgery and radiation, explains Yu. Quality of life data has recently been reported stating that there is better genitourinary and sexual function with 6 months of radiotherapy compared to surgery.

According to Yu, radiotherapy is the quality of life choice for patients versus surgery. More data will have to be reported to determine which treatment is ultimately the most beneficial for patient with prostate cancer.
 


James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses radiotherapy versus surgery for patients with prostate cancer.

There is no survival difference between active surveillance and local therapy such as surgery and radiation, explains Yu. Quality of life data has recently been reported stating that there is better genitourinary and sexual function with 6 months of radiotherapy compared to surgery.

According to Yu, radiotherapy is the quality of life choice for patients versus surgery. More data will have to be reported to determine which treatment is ultimately the most beneficial for patient with prostate cancer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x